| Literature DB >> 35699182 |
Kelly M Stanton1,2,3, Vivian Kienzle1, Donna Lee M Dinnes4, Irina Kotchetkov5, Wendy Jessup4, Leonard Kritharides1,4, David S Celermajer1,2,5, Kerry-Anne Rye6.
Abstract
Background Exercise is associated with a reduced risk of cardiovascular disease. Increased high-density lipoprotein cholesterol (HDL-C) levels are thought to contribute to these benefits, but much of the research in this area has been limited by lack of well-controlled subject selection and exercise interventions. We sought to study the effect of moderate and high-intensity exercise on HDL function, lipid/lipoprotein profile, and other cardiometabolic parameters in a homogeneous population where exercise, daily routine, sleep patterns, and living conditions were carefully controlled. Methods and Results Male Army recruits (n=115, age 22±0.3 years) completed a 12-week moderate-intensity exercise program. A subset of 51 subsequently completed a 15-week high-intensity exercise program. Fitness increased and body fat decreased after moderate- and high-intensity exercise (P<0.001). Moderate-intensity exercise increased HDL-C and apolipoprotein A-I levels (6.6%, 11.6% respectively), and decreased low-density lipoprotein cholesterol and apolipoprotein B levels (7.2%, 4.9% respectively) (all P<0.01). HDL-C and apolipoprotein A-I levels further increased by 8.2% (P<0.001) and 6.3% (P<0.05) after high-intensity exercise. Moderate-intensity exercise increased ABCA-1 (ATP-binding cassette transporter A1) mediated cholesterol efflux by 13.5% (P<0.001), which was sustained after high-intensity exercise. In a selected subset the ability of HDLs to inhibit ICAM-1 (intercellular adhesion molecule-1) expression decreased after the high (P<0.001) but not the moderate-intensity exercise program. Conclusions When controlling for exercise patterns, diet, and sleep, moderate-intensity exercise improved HDL function, lipid/lipoprotein profile, fitness, and body composition. A sequential moderate followed by high-intensity exercise program showed sustained or incremental benefits in these parameters. Improved HDL function may be part of the mechanism by which exercise reduces cardiovascular disease risk.Entities:
Keywords: ATP‐binding cassette transporters; HDL‐C; cholesterol; cholesterol efflux capacity; exercise
Mesh:
Substances:
Year: 2022 PMID: 35699182 PMCID: PMC9238648 DOI: 10.1161/JAHA.121.023386
Source DB: PubMed Journal: J Am Heart Assoc ISSN: 2047-9980 Impact factor: 6.106
Effects of Moderate‐Intensity Exercise on Fitness, Anthropometry, Clinical Characteristics, Plasma Lipid and Apolipoprotein Levels, Markers of Glucose Metabolism, and Inflammation in All Participants
|
Characteristics (n=115) | Baseline | Moderate‐intensity |
|
|---|---|---|---|
| Clinical parameters | |||
| Age, y | 21.9±0.3 | 22.1±0.3 | <0.001 |
| Body mass index, kg/m2 | 24.4±0.3 | 23.8±0.2 | <0.001 |
| Body fat, % | 15.6±0.4 | 12.5±0.3 | <0.001 |
| Systolic BP, mm Hg | 127.4±1.4 | 126.5±1.2 | 0.56 |
| Diastolic BP, mm Hg | 65.8±0.9 | 61.9±0.8 | <0.01 |
| Heart rate, beats/min | 65.3±1.4 | 60.3±1.7 | <0.01 |
| Fitness, multistage fitness test meters | 1546±29 | 1900±25 | <0.001 |
| Est. VO2 max, mL/kg per min | 45.1±0.12 | 50.1±0.26 | <0.001 |
| Pathology | |||
| HDL‐C, mmol/L | 1.36±0.03 | 1.45±0.04 | <0.001 |
| Low‐density lipoprotein cholesterol, mmol/L | 2.65±0.07 | 2.46±0.06 | <0.001 |
| Total cholesterol, mmol/L | 4.32±0.08 | 4.29±0.07 | 0.76 |
| Triglycerides, mmol/L | 0.66 (0.46–0.86) | 0.82 (0.52–1.12) | <0.001 |
| nonHDL‐C, mmol/L | 2.95±0.08 | 2.84±0.07 | 0.06 |
| apoA‐I, mg/mL | 1.38±0.01 | 1.54±0.02 | <0.001 |
| apoA‐II, mg/mL | 0.45±0.01 | 0.40±0.01 | <0.001 |
| apoB, mg/mL | 0.82±0.02 | 0.78±0.02 | <0.01 |
| Glucose, mmol/L | 4.56±0.04 | 5.01±0.04 | <0.001 |
| Insulin, mU/L | 5.41±0.24 | 6.87±0.35 | <0.001 |
| Homeostatic model assessment of insulin resistance | 1.11±0.05 | 1.55±0.09 | <0.001 |
| High‐sensitivity C‐reactive protein, mg/L | 0.40 (0.30–1.0) | 0.60 (0.40–1.30) | <0.01 |
Data represent the mean±SEM or median and interquartile range where data is log transformed. Paired t tests were used for statistical analysis. Apo indicates apolipoprotein; BP, blood pressure; and HDL‐C, high‐density lipoprotein cholesterol.
Raw data median and interquartile range reported, significance is based on log transformed data.
n=61.
Effects of Sequential Moderate and High‐Intensity Exercise Programs on Fitness, Anthropometry, Clinical Characteristics, Plasma Lipid and Apolipoprotein Levels, Markers of Glucose Metabolism, and Inflammation in Participants Who Completed Both Exercise Programs
|
Characteristics (n=51) | Baseline | Moderate intensity | High intensity |
|---|---|---|---|
| Clinical parameters | |||
| Age, y | 21.7±0.4 | 21.9±0.4 | 22.3±0.4 |
| Body mass index, kg/m2 | 24.5±0.3 | 23.9±0.3 | 24.0±0.3 |
| Body fat, % | 15.4±0.5 | 12.3±0.3 | 12.7±0.3 |
| Systolic BP, mm Hg | 127.4±1.4 | 126.5±1.4 | 125.3±1.3 |
| Diastolic BP, mm Hg | 65.8±1.2 | 61.9±1.1 | 68.3±1.6 |
| Heart rate, beats/min | 65.4±1.4 | 59.6±1.7 | 56.8±1.9 |
| Fitness (multistage fitness test meters) | 1585±41 | 1949±35 | 1993±39 |
| Est. VO2 max, mL/kg per min | 46.1±0.7 | 50.8±0.5 | 51.8±0.6 |
| Pathology | |||
| HDL‐C, mmol/L | 1.46±0.05 | 1.58±0.06 | 1.71±0.06 |
| Low‐density lipoprotein cholesterol, mmol/L | 2.49±0.10 | 2.39±0.09 | 2.49±0.10 |
| Total cholesterol, mmol/L | 4.24±0.11 | 4.35±0.12 | 4.58±0.10 |
| Triglycerides, mmol/L | 0.60 (0.50–0.70) | 0.70 (0.6–1.00) | 0.7 (0.6–1.0) |
| Non‐HDL‐C, mmol/L | 2.78±0.11 | 2.77±0.10 | 2.87±0.11 |
| apoA‐I, mg/mL | 1.41±0.03 | 1.60±0.04 | 1.70±0.04 |
| apoA‐II, mg/mL | 0.44±0.01 | 0.40±0.01 | 0.49±0.01 |
| apoB, mg/mL | 0.82±0.03 | 0.79±0.03 | 0.82±0.03 |
| Pre β1‐HDL, µg/mL | 4.16±0.17 | 3.86±0.17 | 4.22±0.21 |
| Glucose, mmol/L | 4.58±0.07 | 5.03±0.07 | 4.85±0.08 |
| Insulin, mU/L | 5.29±0.32 | 6.78±0.40 | 6.47±0.88 |
| Homeostatic model assessment of insulin resistance | 1.10±0.08 | 1.54±0.11 | 1.43±0.21 |
| High‐sensitivity C‐reactive protein, mg/L | 0.50 (0.20–1.10) | 0.60 (0.40–1.50) | 1.00 (0.40–2.00) |
Data represent the mean±SEM or median and interquartile range where data are log transformed. Results are from repeated measures ANOVA with Bonferroni post hoc pairwise comparison testing for multiple comparisons. Apo indicates apolipoprotein; BP, blood pressure; and HDL‐C, high‐density lipoprotein cholesterol.
P<0.001 compared with baseline.
P<0.001 moderate vs high intensity.
P<0.01 compared with baseline.
P<0.05 compared with baseline.
P<0.01 moderate vs high intensity.
P<0.05 moderate vs high intensity.
Raw data median and interquartile range reported, significance is based on log transformed data.
Figure 1Exercise increases ABCA1‐mediated cholesterol efflux and improves the anti‐inflammatory properties of HDLs.
ABCA1‐specific cholesterol efflux at baseline and after moderate‐ and high‐intensity exercise. Chinese hamster ovary cells with tetracycline‐inducible expression of human ABCA1 were loaded with 3H‐cholesterol and incubated for 4 hours in the absence or presence of apoB‐depleted serum as described in the Methods. The percentage of efflux was calculated as radioactivity in the medium relative to the total radioactivity (cells+medium). ABCA1‐specific cholesterol efflux was calculated as the difference in efflux between cells incubated with and without tetracycline and normalized to a standard sample of apoB‐depleted serum (n=51) (A). ICAM‐1 and VCAM‐1 expression in TNF‐α activated HCAECs at baseline and after moderate‐ and high‐intensity (B and C). HCAECs were preincubated for 16 hours with ultracentrifugally isolated HDLs at baseline and after moderate‐ and high‐intensity exercise, then activated for 5 hours with TNF‐α. Expression of ICAM‐1 (n=19) (B) and VCAM‐1 (n=19) (C) was quantified by flow cytometry. Data represent the mean±SEM of triplicate measurements. Repeated measures ANOVA was conducted with Bonferroni post hoc pairwise comparison testing for multiple comparisons. ***P<0.001. ABCA1 indicates ATP‐binding cassette transporter A1; apoB, apolipoprotein; HCAEC, human coronary artery endothelial cell; HDL, high‐density lipoprotein; ICAM‐1, intercellular adhesion molecule 1; MFI, mean fluorescence intensity; TNF‐α, tumor necrosis factor alpha; and VCAM‐1, vascular cell adhesion molecule 1.
Figure 2Correlation between change in cholesterol efflux capacity compared with change in key lipid, lipoproteins, and metabolic parameters from baseline to after moderate‐ and to after high‐intensity exercise.
Correlation between change in cholesterol efflux capacity and change in: (A) ApoA‐I, (B) HDL‐C, (C) pre‐β HDL, (D) ApoB, (E) LDL‐C, (F) TC, (G) TG, (H) glucose level, (I) HOMA‐IR, (J) fitness, (K) body fat %. Graph shown is linear regression analysis. r value based on Spearman correlation. P<0.05 is considered significant. †ln. ApoA‐I indicates apolipoprotein A‐I; ApoB, apolipoprotein; HDL‐C, high‐density lipoprotein cholesterol; HOMA‐IR, homeostatic model assessment of insulin resistance; LDL‐C, low‐density lipoprotein cholesterol; TC, total cholesterol; and TG, triglycerides.
The Effect of Sequential Moderate‐ and High‐Intensity Exercise Programs on HDL Composition
|
Weight (%) (n=19) | Baseline | Moderate intensity | High intensity |
|---|---|---|---|
| Phospholipid | 27.7±1.0 | 28.9±0.6 | 28.6±0.6 |
| Cholesteryl esters | 23.4±0.7 | 22.7±0.5 | 23.0±0.6 |
| Unesterified cholesterol | 5.0±0.4 | 4.8±0.3 | 4.7±0.3 |
| Triglyceride | 1.3 (1.1–2.0) | 1.7 (1.4–2.8) | 1.8 (1.5–2.2) |
| Protein | 42.3±1.6 | 41.5±1.5 | 41.8±1.1 |
| apoA‐I/apoA‐II (mol/mol) | 1.9±0.1 | 2.2±0.1 | 2.1±0.1 |
Data represent the mean±SEM or median and interquartile range. Repeated measures ANOVA was conducted with Bonferroni post hoc pairwise comparison testing for multiple comparisons. Apo indicates apolipoprotein.
Raw data median and interquartile range reported, significance is based on log transformed data.
P<0.05 compared with baseline.
P<0.01 compared with baseline.